Even though Eli Lilly has generated billions of dollars from its weight loss drugs, one particular thing has limited revenue potential. Now, this headwind is set to disappear. And this lack of ...

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases. But the deal is a little different compared to many recent ...

Oct 7 (Reuters) - A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s (LLY.N), opens new tab blockbuster weight loss and ...

Gift 5 articles to anyone you choose each month when you subscribe. Times are good at Eli Lilly. Wall Street’s insatiable appetite for weight-loss drug stocks looks set to turn the company into ...

Eli Lilly's GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list.Yahoo Finance Senior Health Reporter Anjalee Khemlani ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other the Stock That Will Make You Rich in 5-10 Years. The US economy grew by 3% in the ...

ALBANY — Lilly Phillips began her college career as the lone freshman starter on a veteran-laden University at Albany women’s basketball team that won an America East Conference championship.

Eli Lilly has ben able to increase its manufacturing capacity to meet demand for its GLP-1 drugs. The company hopes this will reduce competition from drug compounding businesses. The stock looks ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their medical records for safety reasons, a move that comes as it builds a case ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. The FDA has greenlighted Novartis’ Kisqali, used in ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,150.00. Alec Stranahan ...

Eli Lilly's long-term growth prospects have been secured by the improved supply in H2'24 and the incoming capacity additions from H1'25 onwards. This is on top of the introduction of its D2C ...